Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: Tim Luke who wrote (8619)	11/5/1998 4:45:00 PM
From: Deeber	Read Replies (1) \| Respond to of 119973

TIm...different situation totally with CIEN. Buyout rumors were the driver there, plus it was up from like 8 or so. Also, market sentiment was poor that day, and PAIR (fellow runner) got downgraded also which dragged them both down it seemed. THis is different in a lot of respects. But ya never know...actially CIEN did open higher that day...then market turned.... RG

To: Tim Luke who wrote (8619)	11/5/1998 4:46:00 PM
From: Rock_nj	Respond to of 119973

Different stock, different story. People were buying CIEN hoping for a buyout. It didn't happen and the stock fell.

To: Tim Luke who wrote (8619)	11/5/1998 4:48:00 PM
From: NASDBULL	Read Replies (3) \| Respond to of 119973

Tim: You are right, I have no idea what I'm talking about. I'm just guessing like everyone else. By the way, read this....GERN having a conference call at 5:15 with analysts to discuss "recent corporate events"!!! HUGE!! NASDBULL Geron Research Reproduces 'Immortal' Human Stem Cells (Update1) Geron Research Reproduces 'Immortal' Human Stem Cells (Update1) (Adds details beginning in eighth paragraph.) Washington, Nov. 5 (Bloomberg) -- Research supported by Geron Corp. has isolated and cultured for the first time a special type of human cell that serves as the building block for all other human cells. The cells, cultivated from embryo and fetal tissue, can be prodded to grow into any kind of human cell -- bone, muscle, white blood cell or nerve ending, researchers said. ''Its extremely promising for treating age-related degenerative diseases,'' said Ronald Eastman, president and chief executive officer at Geron. The special ''stem'' cells allow better research on human development, Eastman said. If researchers can determine how to steer their ''differentiation'' or development into different types of mature cells, that could lead to new treatments for diabetes, heart failure and degenerative nerve diseases, he said. Geron funded the work of three separate university research teams working separately on the cells and owns the rights to future uses that might come from the study results. Embargoed studies done by two of the teams were released after the close of trading on U.S. markets today. Before the official release, however, shares in Menlo Park, California-based Geron rose 2 3/8, or 31 percent, to 9 15/16 in trading of 4.3 million shares, almost 40 times the daily average volume for the stock over the past 6 months. Geron said it did not release the studies early. However, in a mid-afternoon release, Geron invited analysts to a 5:15 p.m. EST conference call, saying it wanted to discuss ''recent corporate events.''

To: Tim Luke who wrote (8619)	11/5/1998 4:54:00 PM
From: DebtBomb	Read Replies (2) \| Respond to of 119973

Tim Luke, you sold too early IMO, but nothing wrong with taking profits. GERN is having some big news, now. There will plenty of buyers in the morning, IMO. GERN isn't a BB stock, it's a high quality listed stock that has a good future, although the company is currently in early stages. I have seen this stock move well in the past. Good luck to you.

To: Tim Luke who wrote (8619)	11/5/1998 5:12:00 PM
From: Jane4IceCream	Read Replies (1) \| Respond to of 119973

Tim... I respectfully disagree regarding GERN. The biotechs thrive on stories. This is a good one. Right up there with ENMD and so forth. MM's have a tendency (for whatever reason unknownst to moi) to move the bid/ask much higher on these stories pre-open. Anything can happen. Thats why you see more sensationalism and higher price swings with these issues. Just got off the phone with my sister's husband who is a broker with a national firm in Orange County. He already has had 5 phone calls after market closed today from his customers asking about GERN after seeing or hearing the news on the wires. He also specializes in biotechs and pharmaceuticals (where do you think I got my taste for these stocks from) and many have been aware of GERN's funding of these studies for awhile. Its one of the stocks he mentioned that is being talked about in his office this afternoon. Plus he mentioned he already has 4 pre-market orders for GERN to buy out of the 5 customers that called him directly! Mrs. Cleaver:-)